Welcome to FMU! Taiwanese delegation from LIBO Pharma (Taiwan) visited on Tuesday, March 10
— A New Step Toward Deepening International Collaborative Research and Advancing Fukushima’s Recovery —

2026.03.30
Japanese version is here.

　On March 10, 2026, a delegation from LIBO Pharma Corp., led by CEO Henry LIU, visited our university. The purpose of this visit was to review the progress of ongoing international collaborative research and to discuss future directions for strengthening cooperation between LIBO Pharma and FMU.

Appreciation for Taiwan’s Continued Support Since 2011

　At the outset, FMU Chief Executive and President Seiichi TAKENOSHITA expressed profound gratitude for the generous support extended by the people of Taiwan following the 2011 Great East Japan Earthquake. He also emphasized that our university has advanced its recovery and development under the slogans “Transforming the tragedy of Fukushima into the miracle of Fukushima” and “Turning change into evolution.” He noted that this progress has been made possible thanks to many supporters, including those from Taiwan.

International Joint Research Utilizing a First-in-Class Immunomodulator, “NM‑IL‑12”

　Chair Professor Arifumi HASEGAWA (Department of Radiation Disaster Medicine) and LIBO Pharma Corp. are advancing an international joint research project using NM‑IL‑12, a revolutionary immunomodulatory agent.
　This research aims to develop novel treatments for rare diseases and to explore potential applications for acute radiation syndrome, representing an important contribution to the advancement of medical science. NM-IL-12 is also expected to among the medications stockpiled for significant radiation exposures that may arise during nuclear plant decommissioning and related situations.
　During this visit, the research team presented progress reports and engaged in active discussions and exchanges of ideas.

Building a Cooperative Framework for the Next 10 to 20 Years

　The medical and pharmaceutical fields are undergoing rapid paradigm shifts, making international collaboration increasingly vital. Despite various global challenges, the visit by the LIBO Pharma delegation holds significant meaning for shaping the future of Fukushima’s recovery in particular, and medical innovation in general.
　FMU will continue to promote research and educational activities that contribute to both the local community and the global population through close cooperation with international partners.